Our Top 5 Analyst Questions Sotera Health Company’s Q1 Earnings Call Patrick Donnelly (Citi)asked about the potential impact of tariffs and the company’s confidence in navigating them.

Fintel reports that on May 5, 2025, Goldman Sachs upgraded their outlook for Sotera Health (NasdaqGS:SHC) from Neutral to Buy. Analyst Price Forecast Suggests 17.11% Upside As of April 24, 2025 ...

Goldman Sachs upgrades Sotera Health to Buy, citing tariff immunity, legal clarity, and exposure to Medtech innovation for future growth.

Legal & General Group Plc trimmed its stake in Sotera Health (NASDAQ:SHC – Free Report) by 2.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned ...

Fintel reports that on May 5, 2025, Goldman Sachs upgraded their outlook for Sotera Health (NasdaqGS:SHC) from Neutral to Buy.

Sotera Health goes to market through three businesses – Sterigenics ®, Nordion ® and Nelson Labs ®. Sotera Health is committed to its mission, Safeguarding Global Health ®.

Sotera Health (SHC) stock drops as the company agrees to pay $30.9M to settle ethylene oxide claims tied to a former facility. Read more here.

Sotera Health Co. (Nasdaq: SHC) of Broadview Heights and its Sterigenics subsidiary have finalized nearly $31 million in settlements related to its ethylene oxide claims at its former plant in ...

Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Sotera Health (NASDAQ:SHC – Free Report) by 17.3% during the 4th quarter, according to its most recent 13F filing with the ...

AIA's IPR estoppel limits invalidity defenses in court. Sotera stipulations help avoid PTAB denials by addressing overlap with district court proceedings ...